The global Afamelanotide market size is predicted to grow from US$ 66.33 million in 2025 to US$ 113 million in 2032; it is expected to grow at a CAGR of 8.1% from 2026 to 2032.

Afamelanotide is a synthetic peptide drug, an analog of alpha-melanocyte-stimulating hormone (?-MSH), used as a subcutaneous implant to prevent painful skin reactions from sun exposure in patients with the rare genetic disorder Erythropoietic Protoporphyria (EPP). It works by stimulating melanin (specifically eumelanin) production in the skin, which blocks light and reduces the severe pain, redness, and swelling caused by EPP. Administered as a small implant under the skin, its released slowly over about two months.

Global production of afanotide is projected to reach 3,000 vials by 2025, with an average price of US$22,600 per vial. Gross profit margins typically remain at a high level of 70% to 85%.

Afamelanotide is a synthetic analog of melanocyte-stimulating hormone. Its upstream industry chain mainly consists of peptide raw materials and amino acid monomers, solid-phase synthesis resins and reagents, solvents, lyophilization excipients, sterile packaging materials, and bioanalytical testing services. The upstream focus lies in high-purity peptide synthesis and consistent quality control. Downstream demand is highly concentrated in rare disease and niche dermatology treatments, with its primary use in improving phototolerance for patients with erythropoietic protoporphyria. End users are mainly specialized hospitals, rare disease treatment centers, and reimbursement systems. Given the small and clearly defined patient population, downstream stakeholders prioritize clinical efficacy, safety, ease of administration, and long-term adherence. Payment is often supported by public insurance, special funds, or premium commercial insurance, resulting in relatively low price sensitivity but high requirements for clinical evidence. As real-world data accumulates, downstream applications are gradually expanding toward additional photosensitivity-related indications, while remaining focused on specialist channels and academic promotion.

In terms of industry trends, Afamelanotide products are moving toward indication expansion, optimized delivery methods, and stronger real-world evidence generation. Key growth drivers include supportive orphan drug policies, incentives for rare disease development, and increasing advocacy from patient organizations. Major constraints include a limited patient base that caps market size, high development and regulatory costs, complex manufacturing barriers, and strong dependence on a single core product.

Infinity Market Research newest research report, the Afamelanotide Industry Forecast looks at past sales and reviews total world Afamelanotide sales in 2025, providing a comprehensive analysis by region and market sector of projected Afamelanotide sales for 2026 through 2032. With Afamelanotide sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Afamelanotide industry.

This Insight Report provides a comprehensive analysis of the global Afamelanotide landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Afamelanotide portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Afamelanotide market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Afamelanotide and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Afamelanotide.

This report presents a comprehensive overview, market shares, and growth opportunities of Afamelanotide market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:

    Subcutaneous Implants
    Injectables
    Transdermal Patches
    Oral Preparations
    Topical Preparations
    Segmentation by Chemical Structure:
    ?-MSH Analogs
    Acetate Derivatives
    Free Peptide Derivatives
    Long-Acting Modified Derivatives
    Segmentation by Pharmacological Effects:
    MC1R Selective Agonists
    Melanin Synthesis Stimulants
    Anti-Inflammatory Agents
    Neuroprotective Agents

Segmentation by Application:

    Hematologic Disorders
    Skin Pigmentary Disorders
    Acute Diseases
    Autoimmune Diseases
    Neurodegenerative Diseases

This report also splits the market by region:

    Americas
        United States
        Canada
        Mexico
        Brazil
    APAC
        China
        Japan
        Korea
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        UK
        Italy
        Russia
    Middle East & Africa
        Egypt
        South Africa
        Israel
        Turkey
        GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration.

    Clinuvel Pharmaceuticals
    Evonik Industries
    Hangzhou Go Top Peptide Biotech
    Zhejiang Hengtengfu
    Wepon

Key Questions Addressed in this Report

What is the 10-year outlook for the global Afamelanotide market?
What factors are driving Afamelanotide market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Afamelanotide market opportunities vary by end market size?
How does Afamelanotide break out by Type, by Application?